French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin (CUPIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01514890|
Recruitment Status : Completed
First Posted : January 23, 2012
Last Update Posted : January 24, 2017
|Condition or disease|
|Chronic Hepatitis C|
Methodology: Multicentric French national cohort with prospective collection of data and constitution of biobank, in HCV genotype 1 patients with compensated cirrhosis who failed to eradicate HCV with the combination PEG-IFN and RBV, treated with protease inhibitor (telaprevir or boceprevir), PEG-IFN and RBV, included in the French Early Access Program for the use of protease inhibitors or after approval of these drugs through the the marketing authorization.
Primary objective: Evaluate the efficacy defined by the sustained virological response (SVR), in patients with compensated cirrhosis treated with PEG-IFN, RBV and telaprevir or boceprevir in the French Early Access Program for the use of protease inhibitors or after the approval of these drugs.
Estimated enrollment: 900 patients treated in the French Early Access Program for the use of protease inhibitors and after the marketing authorization approval.
- with telaprevir: triple combination with PEG-IFN alfa-2a, 180 µg/week, ribavirin 1000 to 1200 mg/d according the body weight and telaprevir 750 mg/8h, for 12 weeks followed by PEG-IFN and RBV for 36 weeks for a total duration of treatment of 48 weeks.
- or with boceprevir: triple combination with PEG-IFN alfa-2b, 1,5 µg/kg/week, RBV 800 to 1400 mg/d according the body weight and boceprevir 800 mg/8h. The treatment will begin after a lead in phase of PEG-IFN and RBV for 4 weeks, followed by a triple combination (PEG-IFN, RBV and boceprevir)during 44 weeks for a total duration of treatment of 48 weeks.
- study start date: February 2011
- enrollment period: 14 months
- subject participation duration: 12 months of treatment and 12 months of follow-up = 24 months
- total study duration: 38 months. The last visit of the last enrolled patient is prevised in February 2014, the end of analysis on biobank in May 2014 (long term follow up of resistant mutants).
Some blood samples will be preserved for scientific future research.
Study design: national French multicentric cohort in patients with HCV-related cirrhosis treated in the French Early Access Program for the use of boceprevir or telaprevir or after the marketing authorization approval of these drugs associated with PEG-IFN and RBV with a collection of clinical and biological data and constitution of a biobank.
|Study Type :||Observational|
|Actual Enrollment :||675 participants|
|Official Title:||Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) Included in the French Early Access Program for the Use of Protease Inhibitors in Genotype 1 Patients Who Failed to Eradicate HCV With a Previous Standard PEG-IFN and RBV Combination.|
|Actual Study Start Date :||February 2011|
|Actual Primary Completion Date :||March 2014|
|Actual Study Completion Date :||March 2014|
- Rate of sustained virological response (SVR) defined by an undetectable RNA by real-time PCR. [ Time Frame: 6 months after discontinuation of therapy (at week 72) ]
- Virological response during and after the treatment with determination of HCV RNA levels as prevised by the French Early Access Program for the use of protease inhibitors and after the approval. [ Time Frame: at D0, W4, W8, W12, W24, W48 and 12 (W60) and 24 (W72) weeks after the discontinuation of treatment ]
This will allow to define:
- rate of non response (detectable RNA during the treatment)
- rate of virological breakthrough (undetectable HCV RNA then detectable during the treatment)
- rate of virological relapse after the discontinuation of treatment (undetectable HCV RNA at the end of therapy then detectable after the treatment)
- early viral kinetic [ Time Frame: at the D0, W1, W2 and W4 ]
- Rate of premature discontinuation of protease inhibitor, RBV and/or PEG-IFN [ Time Frame: in may 2014 (3 month after study completion date) ]
- occurrence of resistant mutants in partial responders (detectable RNA) or after the occurrence of virological breakthrough and long term evolution of these mutations (on serum bank) [ Time Frame: in may 2014 (3 month after study completion date) ]
- Evolution of quality of life scores [ Time Frame: in may 2014 (3 month after study completion date) ]
- Evaluation of therapeutic observance with auto-questionnaires [ Time Frame: in may 2014 (3 month after study completion date) ]
- Rate of adaptation of dosage of protease inhibitors, RBV and/or PEG-IFN [ Time Frame: in may 2014 (3 month after study completion date) ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01514890
|Hôpital Henri Mondor|
|Créteil, France, 94000|
|Principal Investigator:||Christophe HEZODE||GHU H. Mondor|
|Study Chair:||Fabrice CARRAT, Methodologist||Unité INSERM 707|